Dosing Woes For VBI Vaccines As Share Price Plummets On Hep B Study Results

 
• By Jo Shorthouse

Despite positive results in the latest Phase III PROTECT study of its hepatitis B vaccine, VBI Vaccines failed to show non-inferiority at two doses, leaving it trailing behind competitor Dynavax and its established two-dose product.

Arch_Hands
The PROTECT study tested Sci-B-Vac against GSK's Engerix-B • Source: Shutterstock

More from Anti-infective

More from Therapy Areas